View Mode:
JS
Pipeline Tracker
Pipeline Assets
Sort by:
| Asset | Company | Therapeutic Area | MOA | Phase | Last Update | Actions |
|---|---|---|---|---|---|---|
|
PF-06939926
fordadistrogene movaparvovec
|
Pfizer
|
Rare Disease
Duchenne muscular dystrophy
|
Gene therapy
|
Phase 3 | 2h ago | View Details |
|
Kesimpta
ofatumumab
|
Novartis
|
Neurology
Multiple Sclerosis
|
Anti-CD20 mAb
|
Approved | 5h ago | View Details |
|
KEYTRUDA
pembrolizumab
|
Merck
|
Oncology
NSCLC
|
PD-1 inhibitor
|
Phase 3 | 8h ago | View Details |
|
TAGRISSO
osimertinib
|
AstraZeneca
|
Oncology
NSCLC
|
EGFR TKI
|
Phase 3 | 1d ago | View Details |
|
Upadacitinib
RINVOQ
|
AbbVie
|
Immunology
Rheumatoid Arthritis
|
JAK inhibitor
|
Phase 3 | 2d ago | View Details |
Showing 1 to 5 of 42 assets
© 2025 CI Agent. All rights reserved.